Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS

The third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), osimertinib, aumolertinib, and furmonertinib represent a new treatment option for patients with EGFR p.Thr790 Met (T790 M)-mutated non-small cell lung cancer (NSCLC). Currently, there are no studies reporti...

Full description

Bibliographic Details
Main Authors: Ying Li, Lu Meng, Yinling Ma, Yajing Li, Xiaoqing Xing, Caihui Guo, Zhanjun Dong
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Molecules
Subjects:
UPLC-MS/MS
osimertinib
aumolertinib
furmonertinib
therapeutic drug monitoring
Online Access:https://www.mdpi.com/1420-3049/27/14/4474

Internet

https://www.mdpi.com/1420-3049/27/14/4474

Similar Items